CHESHIRE, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced that the
Company will host an Investor Day on Thursday, December 10, 2015 from
12:00 p.m. to 5:00 p.m. Eastern Standard Time in New York City.
Alexion's leadership team will highlight the continued advancement of
the Company's highly innovative early and late-stage pipeline which is
focused on serving patients with devastating and rare diseases. The
company will also provide updates on key aspects of its long-term growth
strategy for its complement and metabolic franchises.
Webcast/Conference Call Information
The presentation will be broadcast via a live webcast which can be
accessed on the Investor page of Alexion's website at: http://ir.alexionpharm.com.
A replay of the webcast will be archived on the website following the
presentation. To participate in this conference call, dial 866-546-3377
(USA) or 719-234-7872 (International), passcode 737 644 3057 shortly
before 12:00 p.m. ET.
About Alexion
Alexion is a global biopharmaceutical company focused on developing and
delivering life-transforming therapies for patients with devastating and
rare disorders. Alexion developed and commercializes
Soliris® (eculizumab), the first and only approved complement inhibitor
to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS), two life-threatening
ultra-rare disorders. As the global leader in complement inhibition,
Alexion is strengthening and broadening its portfolio of complement
inhibitors, including evaluating potential indications for eculizumab in
additional severe and ultra-rare disorders. Alexion's metabolic
franchise includes two highly innovative enzyme replacement therapies
for patients with life-threatening and ultra-rare disorders, Strensiq™
(asfotase alfa) to treat patients with hypophosphatasia (HPP) and
Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase
deficiency (LAL-D). In addition, Alexion is advancing the most robust
rare disease pipeline in the biotech industry, with highly innovative
product candidates in multiple therapeutic areas. This press release and
further information about Alexion can be found at: www.alexion.com.
[ALXN-G]
View source version on businesswire.com: http://www.businesswire.com/news/home/20151119005756/en/
Alexion Pharmaceuticals Inc.
Media:
Stephanie Fagan,
203-271-8223
Senior Vice President, Corporate Communications
or
Kim
Diamond, 203-439-9600
Executive Director, Corporate Communications
or
Investors:
Elena
Ridloff, CFA, 203-699-7722
Executive Director, Investor Relations
Source: Alexion Pharmaceuticals Inc.
News Provided by Acquire Media